![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
Schrödinger, Inc. announced it has entered into a three-year agreement with Google Cloud to substantially increase the speed and capacity of its physics-based computational platform for drug discovery. As part of the agreement, Schrödinger has selected Google Cloud as the preferred cloud platform for its leading simulation software.
The strategic partnership gives Schrödinger’s drug discovery team access to the capacity equivalent of the world’s most powerful supercomputers by harnessing thousands of Google Cloud GPUs, which are designed to accelerate complex processes such as large-scale physics-based methods and machine learning through parallel computing. This expanded capacity is designed to further enable Schrödinger and its drug discovery collaborators to rapidly predict critical properties of billions of molecules per week.
“We’re excited to harness Google Cloud’s highly scalable system to run extensive free energy calculations to assess binding affinities through our compute-intensive FEP+ application. This partnership also enables us to further leverage BigQuery to analyze important molecular properties nearly instantaneously,” said Shane Brauner, Schrödinger’s Chief Information Officer. “This partnership is expected to allow us to expand the use of our physics-based computational platform to continue to rapidly explore very large swaths of chemical space.”
“Our collaboration with Schrödinger has the potential to improve drug discovery for research and life science organizations by helping the industry move more quickly to identify molecules that can be developed into important therapeutics,” said Rob Enslin, President, Google Cloud. “We are thrilled to work closely with them as part of our long-running partnership.”
About Schrödinger
Schrödinger’s industry-leading computational platform to accelerate drug discovery and materials design is deployed by leading biopharmaceutical and industrial companies, academic institutions and government laboratories worldwide. In addition to this global business, Schrödinger is also applying its computational platform to a robust pipeline of drug discovery programs in collaboration with pharmaceutical companies and has co-founded leading biotech companies. In addition, Schrödinger is using its platform to advance a pipeline of internal, wholly-owned drug discovery programs. Schrödinger’s significant and ongoing investment in basic research continues to drive advances in its computational platform. Founded in 1990, Schrödinger has over 400 employees in its New York City headquarters and around the world.
